JP2011504104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504104A5 JP2011504104A5 JP2010533510A JP2010533510A JP2011504104A5 JP 2011504104 A5 JP2011504104 A5 JP 2011504104A5 JP 2010533510 A JP2010533510 A JP 2010533510A JP 2010533510 A JP2010533510 A JP 2010533510A JP 2011504104 A5 JP2011504104 A5 JP 2011504104A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- poxvirus
- permease
- suicide gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 7
- 108090000301 Membrane transport proteins Proteins 0.000 claims 4
- 102000003939 Membrane transport proteins Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 3
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 3
- 241000700618 Vaccinia virus Species 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 101100502554 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FCY1 gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000002997 osteoclast Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100226898 Candida albicans (strain SC5314 / ATCC MYA-2876) FCA1 gene Proteins 0.000 claims 1
- 108050000190 Cytosine permeases Proteins 0.000 claims 1
- 101000807008 Homo sapiens Uracil phosphoribosyltransferase homolog Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 101100502558 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FCY2 gene Proteins 0.000 claims 1
- 102100037717 Uracil phosphoribosyltransferase homolog Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010087864 purine permease Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301557.0 | 2007-11-19 | ||
| EP07301557 | 2007-11-19 | ||
| PCT/EP2008/009720 WO2009065546A1 (en) | 2007-11-19 | 2008-11-17 | Poxviral oncolytic vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504104A JP2011504104A (ja) | 2011-02-03 |
| JP2011504104A5 true JP2011504104A5 (enExample) | 2011-12-08 |
| JP5710261B2 JP5710261B2 (ja) | 2015-04-30 |
Family
ID=40377657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533510A Active JP5710261B2 (ja) | 2007-11-19 | 2008-11-17 | ポックスウイルス腫瘍細胞崩壊性ベクター |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8778328B2 (enExample) |
| EP (1) | EP2212345B1 (enExample) |
| JP (1) | JP5710261B2 (enExample) |
| KR (1) | KR101542276B1 (enExample) |
| CN (2) | CN102703389B (enExample) |
| AU (1) | AU2008328257B2 (enExample) |
| BR (1) | BRPI0820576B1 (enExample) |
| CA (1) | CA2705869C (enExample) |
| CO (1) | CO6210754A2 (enExample) |
| CR (1) | CR11519A (enExample) |
| DK (1) | DK2212345T3 (enExample) |
| EC (1) | ECSP10010288A (enExample) |
| ES (1) | ES2567564T3 (enExample) |
| HU (1) | HUE028637T2 (enExample) |
| IL (2) | IL204538A (enExample) |
| MX (1) | MX2010005269A (enExample) |
| NZ (1) | NZ584199A (enExample) |
| PL (1) | PL2212345T3 (enExample) |
| RU (1) | RU2503717C2 (enExample) |
| WO (1) | WO2009065546A1 (enExample) |
| ZA (1) | ZA201003461B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212423B1 (en) * | 2007-11-19 | 2015-02-11 | Transgene SA | Poxviral oncolytic vectors |
| US9687515B2 (en) * | 2007-11-19 | 2017-06-27 | Transgene S.A. | Poxviral oncolytic vectors |
| CA2744294A1 (en) | 2009-01-13 | 2010-07-22 | Transgene Sa | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| SG176554A1 (en) | 2009-05-12 | 2012-01-30 | Transgene Sa | Method for orthopoxvirus production and purification |
| CA2709292A1 (en) | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
| EP2452194B1 (en) | 2009-07-10 | 2015-11-11 | Transgene SA | Biomarker for selecting patients and related methods |
| WO2013004658A1 (en) | 2011-07-01 | 2013-01-10 | Transgene Sa | Formulations of 5-fluorocytosine and uses thereof. |
| KR101370620B1 (ko) * | 2011-08-05 | 2014-03-06 | 한국생명공학연구원 | 다람쥐폭스바이러스를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| KR102457060B1 (ko) * | 2014-04-10 | 2022-10-19 | 트랜스진 | 폭스바이러스 종양용해 벡터 |
| ES2833425T3 (es) * | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| US10517943B2 (en) | 2014-12-01 | 2019-12-31 | Transgene S.A. | Stable liquid vaccinia virus formulations |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| JP6731646B2 (ja) * | 2016-07-13 | 2020-07-29 | 国立大学法人鳥取大学 | 外来遺伝子発現ワクシニアウイルスの製造方法 |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| CA3045228C (en) | 2016-12-28 | 2024-01-02 | Transgene Sa | Oncolytic viruses and therapeutic molecules |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| CA3093093A1 (en) | 2018-03-07 | 2019-09-12 | Transgene | Parapoxvirus vectors |
| CN110396504A (zh) * | 2018-04-25 | 2019-11-01 | 江苏省原子医学研究所 | 一种具有肿瘤靶向性的重组痘苗病毒及其制备方法、用途 |
| US20210236619A1 (en) * | 2018-05-02 | 2021-08-05 | Tonix Pharma Holdings Limited | Stem cells comprising synthetic chimeric vaccinia virus and methods of using them |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3617230A1 (en) | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN113454231A (zh) * | 2018-12-21 | 2021-09-28 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
| CA3124773A1 (en) | 2018-12-28 | 2020-07-02 | Transgene | M2-defective poxvirus |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR102819295B1 (ko) | 2019-08-09 | 2025-06-10 | 케이엠 바이올로직스 가부시키가이샤 | 종양 용해성 백시니아 바이러스 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| WO2023025899A2 (en) | 2021-08-26 | 2023-03-02 | Transgene | Delivery system for targeting genes of the interferon pathway |
| TW202321458A (zh) | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| KR20250022783A (ko) | 2022-06-10 | 2025-02-17 | 트랜스진 | 인터루킨-12를 발현하는 재조합 바이러스 |
| CN119654339A (zh) | 2022-07-01 | 2025-03-18 | 特兰斯吉恩股份有限公司 | 包含表面活性蛋白-d和tnfsf成员的融合蛋白 |
| AU2023313118A1 (en) | 2022-07-27 | 2025-03-06 | Astrazeneca Ab | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
| KR20250052416A (ko) | 2022-08-18 | 2025-04-18 | 트랜스진 | 키메라 폭스바이러스 |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| DE4090351T1 (de) * | 1989-03-08 | 1997-07-24 | Health Research Inc | Rekombinantes Pockenvirus-Wirtsselektionssystem |
| US5759552A (en) * | 1991-03-07 | 1998-06-02 | Virogenetics Corporation | Marek's disease virus recombinant poxvirus vaccine |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
| GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| IL106038A0 (en) * | 1992-06-16 | 1993-10-20 | Commw Scient Ind Res Org | Recombinant entomopoxvirus |
| FR2777570A1 (fr) * | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| AU5446700A (en) * | 1999-05-28 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| CA2521744A1 (en) * | 2003-04-15 | 2004-10-28 | Sanofi Pasteur Limited | Tumor antigens bfa-5 for prevention and/or treatment of cancer |
| MXPA05013879A (es) * | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| CA2709292A1 (en) * | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
-
2008
- 2008-11-17 DK DK08852947.4T patent/DK2212345T3/en active
- 2008-11-17 NZ NZ584199A patent/NZ584199A/en unknown
- 2008-11-17 WO PCT/EP2008/009720 patent/WO2009065546A1/en not_active Ceased
- 2008-11-17 CA CA2705869A patent/CA2705869C/en active Active
- 2008-11-17 HU HUE08852947A patent/HUE028637T2/en unknown
- 2008-11-17 CN CN201210160650.3A patent/CN102703389B/zh active Active
- 2008-11-17 EP EP08852947.4A patent/EP2212345B1/en active Active
- 2008-11-17 PL PL08852947T patent/PL2212345T3/pl unknown
- 2008-11-17 AU AU2008328257A patent/AU2008328257B2/en active Active
- 2008-11-17 JP JP2010533510A patent/JP5710261B2/ja active Active
- 2008-11-17 RU RU2010124616/10A patent/RU2503717C2/ru active
- 2008-11-17 CN CN200880116834.1A patent/CN101868474B/zh active Active
- 2008-11-17 MX MX2010005269A patent/MX2010005269A/es active IP Right Grant
- 2008-11-17 BR BRPI0820576-0A patent/BRPI0820576B1/pt active IP Right Grant
- 2008-11-17 ES ES08852947.4T patent/ES2567564T3/es active Active
- 2008-11-17 US US12/743,407 patent/US8778328B2/en active Active
- 2008-11-17 KR KR1020107010922A patent/KR101542276B1/ko active Active
-
2010
- 2010-03-16 IL IL204538A patent/IL204538A/en active IP Right Grant
- 2010-05-17 ZA ZA2010/03461A patent/ZA201003461B/en unknown
- 2010-06-18 CO CO10073782A patent/CO6210754A2/es not_active Application Discontinuation
- 2010-06-18 EC EC2010010288A patent/ECSP10010288A/es unknown
- 2010-06-18 CR CR11519A patent/CR11519A/es not_active Application Discontinuation
-
2012
- 2012-06-26 IL IL220653A patent/IL220653A/en active IP Right Grant
- 2012-09-15 US US13/620,983 patent/US20130039891A1/en not_active Abandoned
-
2013
- 2013-02-27 US US13/778,235 patent/US9884080B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504105A5 (enExample) | ||
| RU2013129678A (ru) | Поксвирусные онколитические векторы | |
| CA2705869A1 (en) | Poxviral oncolytic vectors | |
| US11466059B2 (en) | Modified protein | |
| US20210290604A1 (en) | Compounds for treatment of inflammatory bowel disease and methods thereof | |
| ES2568755T3 (es) | Inmunoterapia para VHC | |
| EP3129037B1 (en) | Poxviral oncolytic vectors | |
| CN112789046A (zh) | 地尔硫卓用于治疗微生物感染 | |
| KR101603838B1 (ko) | 브루셀라 균주 유래 ｎｄｋ 재조합 항원을 이용한 브루셀라 감염증 예방 방법 | |
| CA3168943A1 (en) | Ligand-mediated delivery of therapeutic proteins and the uses thereof | |
| Marcellin et al. | THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102); PRELIMINARY ANALYSIS: 481 | |
| US9687515B2 (en) | Poxviral oncolytic vectors | |
| CN115697383A (zh) | 治疗病毒感染和健康问题的方法 | |
| Snoeck et al. | Therapy of poxvirus infections | |
| CN117562913A (zh) | 连翘活性成分组合在制备拮抗SARS-CoV-2突变毒株的药物中的应用 | |
| CN101642462B (zh) | 一种肿瘤抑制剂nrn1sr42 | |
| CN101503437B (zh) | 核酸分子si-cypj-4及其在制备抗癌药物中的应用 | |
| KR20160049312A (ko) | 항암제 부작용의 경감용 조성물 | |
| CN121895434A (zh) | 一种抗病毒多肽及其应用 | |
| CN114929212A (zh) | 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合 | |
| HK1230971B (en) | Poxviral oncolytic vectors | |
| HK1230971A1 (en) | Poxviral oncolytic vectors | |
| KR20180077133A (ko) | Ｎ-메타노카르바티미딘을 이용한 대상포진의 치료방법 | |
| CN101503443A (zh) | 核酸分子si-cypj-22及其在制备抗癌药物中的应用 | |
| CN101503438A (zh) | 核酸分子si-cypj-5及其在制备抗癌药物中的应用 |